Phase I, First-in-Human Trial Evaluating BI 1387446 Alone and in Combination with BI 754091 in Solid Tumors
Study Evaluating BI 1387446 Alone and in Combination with BI 754091 in Solid Tumors
Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS6697
U.S. Govt. ID: NCT04147234
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test the safety and effectiveness of the study drug, BI 1387446, given alone or combined with the study drug, BI 754091, in subjects with different types of advanced cancer. BI 1387446 will be injected directly into at least one tumor site. BI 754091 will be given by intravenous (IV) infusion, which is a slow injection of the study drug directly into a vein. Both of these drugs are immunotherapy drugs. The researchers hope that these drugs will activate a person's immune system to work against their cancer. BI 1387446 given alone and in combination with BI 754091 has been tested in animals but not yet in people. Cancers include: Bladder cancer, breast cancer, ovarian cancer, kidney/adrenal cancer, liver cancer, lung cancer, melanoma, and prostate cancer.
This study is closed
Matthew Ingham, MD
Do You Qualify?
Have you been diagnosed with an advanced, unresectable and/or metastatic malignant solid tumor? Yes No
Do you have a history of brain metastases? Yes No
Are you 18 years of age or older? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator